CNS

CNS refers to central nervous system diseases such as depression, schizophrenia, epilepsy, Alzheimer's disease, Parkinson's disease, and other neurological or psychiatric conditions. Companies on this page are grouped by their exposure to brain and nervous system therapeutics.

Why watch CNS

This page combines a company index, a watch action, and the newest relevant feed items in one place so readers can monitor a biotech theme without scanning each company one by one.

Latest CNS news

The latest feed items from companies currently grouped under CNS.

1. 01
   2026-10-08 05:00 EST

   ADXNAddex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia

   Source: Addex Therapeutics

2. 02
   2026-10-07 11:00 EST

   AXSMAxsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2

   Source: Axsome

3. 03
   2026-10-06 11:05 EST

   PMNProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer

   Source: ProMIS Neurosciences

4. 04
   2026-10-06 10:00 EST

   MNOVMediciNova to Participate in the Maxim Growth Summit

   Source: MediciNova

5. 05
   2026-10-06 05:30 EST

   SNYCommuniqué de presse : Mise en ligne du document «Q3 2026 aide-mémoire »

   Source: Sanofi

6. 06
   2026-10-06 05:30 EST

   SNYPress Release : Availability of the aide-mémoire for Q3 2026 results

   Source: Sanofi

7. 07
   2026-10-05 13:17 EST

   NMTCNeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order

   Source: NeuroOne Medical Technologies

8. 08
   2026-10-05 11:05 EST

   ATHEAlterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders

   Source: Alterity Therapeutics

9. 09
   2026-10-02 21:00 EST

   XERSXeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

   Source: Xeris Pharmaceuticals

10. 10
    2026-10-02 20:01 EST

    XENEXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Source: Xenon

11. 11
    2026-10-02 20:01 EST

    PRAXPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Source: Praxis Precision Medicines

12. 12
    2026-10-02 20:01 EST

    IKTInhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Source: Inhibikase Therapeutics

13. 13
    2026-10-02 15:20 EST

    BIIBBiogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus

    Source: Biogen

14. 14
    2026-10-02 12:00 EST

    TSHATaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Source: Taysha Gene Therapies

15. 15
    2026-10-02 12:00 EST

    TEVATeva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome

    Source: Teva Pharmaceutical Industries

16. 16
    2026-10-02 12:00 EST

    TEVAJournal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients

    Source: Teva Pharmaceutical Industries

17. 17
    2026-10-02 05:00 EST

    ADXNAddex Therapeutics Announces Executive Management Changes

    Source: Addex Therapeutics

18. 18
    2026-10-01 13:28 EST

    GANXGain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration

    Source: Gain Therapeutics

19. 19
    2026-10-01 12:05 EST

    HRMYHarmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days

    Source: Harmony Biosciences

20. 20
    2026-10-01 12:00 EST

    TSHATaysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting

    Source: Taysha Gene Therapies

Companies in CNS

89 companies tagged with CNS.

Frequently Asked Questions